Skip to content

US · HALO · BIOTECHNOLOGY

Halozyme Therapeutics, Inc. (HALO) intrinsic value and stock valuation

$91.35as of 2026-11-21 · Mkt cap 9.91B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Halozyme Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values HALO with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from HALO’s statements →

Halozyme Therapeutics, Inc. Graham Number

Graham Number: $4.92d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92130 halozyme.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$1.4B+39.2% 5y CAGRd
20112025
Net income
$316.9M+19.7% 5y CAGRd
20112025
Free cash flow
$644.6M+64.8% 5y CAGRd
20112025
Total equity
$48.8M-20.2% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$1.4B$1.02B$829.3M$660.1M$443.3M
Operating income$816.3M$551.5M$337.6M$267.5M$275.9M
Net income$316.9M$444.1M$281.6M$202.1M$402.7M
EPSd$2.56M$3.43M$2.1M$1.44M$2.74M
Operating cash flow$651.6M$479.1M$388.6M$240.1M$299.4M
Capital expenditure-$-6.97M-$-10.7M-$-15.29M-$-4.81M-$-1.46M
Free cash flow$644.6M$468.4M$373.3M$235.3M$298M
Total assets$2.53B$2.06B$1.73B$1.84B$1.1B
Total debt$2.14B$1.51B$1.5B$1.51B$876.7M
Net debt$2.01B$1.39B$1.38B$1.27B$758M
Total equity$48.8M$363.8M$83.8M$169.8M$197M
Cash and short-term investments$142.8M$596.1M$336M$362.8M$740.9M
Income statement
20252024202320222021
Revenue$1.4B$1.02B$829.3M$660.1M$443.3M
Cost of revenue$305.4M$159.4M$192.4M$139.3M$81.4M
Gross profit$1.09B$855.9M$636.9M$520.8M$361.9M
Research and development expenses$81.5M$79.1M$76.4M$66.6M$35.7M
Selling, general and administrative expenses$193.4M$154.3M$149.2M$143.5M$50.3M
Other expenses$0.00$71.1M$73.8M$43.2M$0.00
Operating expenses$274.9M$304.4M$299.3M$253.3M$86M
Cost and expenses$580.3M$463.9M$491.7M$392.6M$167.4M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$18.1M$18.1M$18.8M$17M$7.53M
Depreciation and amortization$88.1M$81.3M$84.9M$49.6M$3M
Ebitda$573.1M$656.5M$452M$315.5M$259M
Operating income$816.3M$551.5M$337.6M$267.5M$275.9M
Total other income/expenses, net-$-349.42M$5.66M$10.8M-$-18.61M-$-27.38M
Income before tax$466.9M$557.1M$348.3M$248.9M$248.5M
Income tax expense$150M$113M$66.7M$46.8M-$-154.19M
Net income$316.9M$444.1M$281.6M$202.1M$402.7M
Weighted average shares outstanding$119.8M$126.8M$131.9M$136.8M$140.7M
Weighted average diluted shares outstanding$123.9M$129.4M$134.2M$140.6M$146.8M
Balance sheet
20252024202320222021
Cash and short-term investments$142.8M$596.1M$336M$362.8M$740.9M
Net receivables$441.3M$308.5M$234.2M$231.1M$91M
Inventory$176.5M$141.9M$127.6M$100.1M$53.9M
Total current assets$825.2M$1.09B$746.4M$739M$926.3M
Property, plant and equipment, net$82.1M$75M$74.9M$75.6M$8.79M
Goodwill and intangible assets$1.56B$818.7M$889.7M$955.7M$0.00
Long-term investments$0.00$0.00$0.00$0.00$500K
Total non-current assets$1.7B$978.1M$986.9M$1.1B$178.1M
Total assets$2.53B$2.06B$1.73B$1.84B$1.1B
Accounts payable$20.9M$10.3M$11.8M$17.7M$1.54M
Short-term debt$0.00$0.00$0.00$13.3M$89.4M
Deferred revenue$0.00$0.00$0.00$3.25M$1.75M
Total current liabilities$177.1M$139.1M$112.5M$130.8M$117.2M
Long-term debt$2.14B$1.51B$1.5B$1.49B$787.3M
Deferred revenue, non-current$0.00$0.00$0.00$2.25M$2.53M
Total non-current liabilities$2.3B$1.56B$1.54B$1.54B$790.3M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$2.48B$1.7B$1.65B$1.67B$907.5M
Common stock$120K$120K$130K$140K$140K
Retained earnings$54.8M$359.9M$90.6M$143.2M-$-58.91M
Accumulated other comprehensive income (loss)-$-18.09M$3.83M-$-9.28M-$-920K-$-620K
Total equity$48.8M$363.8M$83.8M$169.8M$197M
Total investments$9M$480.2M$217.6M$128.6M$622.7M
Total debt$2.14B$1.51B$1.5B$1.51B$876.7M
Net debt$2.01B$1.39B$1.38B$1.27B$758M
Cash flow statement
20252024202320222021
Net income$316.9M$444.1M$281.6M$202.1M$402.7M
Depreciation and amortization$88.1M$88.7M$84.9M$57.5M$6.64M
Stock-based compensation$51.6M$43.4M$36.6M$24.4M$20.8M
Change in working capital-$-152.26M-$-136.27M-$-38.67M-$-110.49M$2.57M
Accounts receivable-$-128.06M-$-74.25M-$-3.34M-$-83.94M$6.75M
Inventory$2.55M-$-67.38M-$-26.88M-$-17.48M$7.37M
Accounts payable$0.00$0.00-$-12.55M$0.00$0.00
Net cash provided by operating activities$651.6M$479.1M$388.6M$240.1M$299.4M
Investments in property, plant and equipment-$-6.97M-$-10.7M-$-15.29M-$-4.81M-$-1.46M
Acquisitions, net-$-725.97M$0.00$0.00-$-999.12M$0.00
Net cash used for investing activities-$-545.81M-$-262.72M-$-96.91M-$-487M-$-406.29M
Common stock issued$21.8M$0.00$0.00$0.00$0.00
Common stock repurchased-$-342.37M-$-250M-$-402.38M-$-200M-$-350.06M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-85.17M-$-218.86M-$-407.99M$362.4M$77.9M
Net change in cash$20.6M-$-2.52M-$-116.33M$115.5M-$-28.98M
Cash at end of period$136.4M$115.9M$118.4M$234.7M$119.2M
Operating cash flow$651.6M$479.1M$388.6M$240.1M$299.4M
Capital expenditure-$-6.97M-$-10.7M-$-15.29M-$-4.81M-$-1.46M
Free cash flow$644.6M$468.4M$373.3M$235.3M$298M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Halozyme Therapeutics, Inc.

        Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.

        CEO
        Helen I. Torley
        Employees
        423
        Beta
        0.84

        Explore

        Frequently asked questions

        What is the intrinsic value of Halozyme Therapeutics, Inc. (HALO)?

        Halozyme Therapeutics, Inc. (HALO) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is HALO undervalued?

        HALO trades at a price of $91.35 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.